Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
WuXi AppTec helps drug companies discover, test, and manufacture medicines without having to build all the labs and factories themselves.
WuXi AppTec is a company that big drugmakers and small biotech startups hire to do the messy, expensive work of turning a molecule into a medicine. Think of it as the back kitchen for the drug industry: a pharma company comes up with an idea, and WuXi chops, stirs, and taste-tests it — running chemistry experiments, safety tests on animals and cells, and small clinical trials in people — so the client can focus on the science and the marketing. Crucially, WuXi doesn't own the drugs it works on; it gets paid a fee for the service, the same way a contract manufacturer gets paid to build phones it will never sell under its own name. Its customers are thousands of drug companies around the world, from tiny startups with one promising idea to giants like Pfizer and Merck.
The business splits into a few main pieces. The biggest by far is WuXi Chemistry, which does small-molecule drug discovery and manufacturing — this is roughly two-thirds of revenue and includes making the active ingredients inside pills at commercial scale, plus the fast-growing "TIDES" line that makes complex injectable medicines like GLP-1 weight-loss and diabetes drugs. Second is WuXi Testing, which runs lab tests and clinical research for clients, around a fifth of revenue and more sensitive to biotech funding cycles. Third is WuXi Biology, which does early-stage disease research, also around a fifth. Revenue has been climbing fast — the company booked roughly $5.7 billion in 2024, up around 15% year-over-year — though growth has cooled from the pandemic-era boom.
The thing to watch is politics, not science. The U.S. has proposed legislation (the BIOSECURE Act) that could restrict American drugmakers from working with certain Chinese biotech suppliers, and WuXi is squarely in the crosshairs. That threat is the main reason the stock has been volatile despite steady profits. WuXi has tried to adapt by building more capacity in the U.S. and Europe, and by leaning into the TIDES boom as demand for weight-loss drug ingredients surges. It generates strong free cash flow, which it plows back into new labs and factories and pays out partly as dividends. The founder, Ge Li, started the company in 2000 after returning from the U.S., betting that China's low costs and deep pool of science graduates could become the world's drug-development workshop. For now, that bet has largely paid off — the question is whether
Saved answer · last researched 11 Oct 2026